GLOBUS MEDICAL (GMED) Stock: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$75.60
1.19 (1.60%)
▲
5d:
+1.45%
30d:
-6.27%
90d:
-6.09%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$127.09
Based on 6.0% avg growth
INTRINSIC VALUE TODAY
$78.91
4.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $75.60, which is considered fair relative to its 30-day fair value range of $73.66 to $81.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.0) compared to its historical average (17.6). Remarkably, the market is currently pricing in an annual earnings decline of 7.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $76.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $100.92 (+33.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $76.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $100.92 (+33.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$73.66 -
$81.56
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.5% below Wall St target ($100.92)
- CAUTION: Bottoming setup, but lagging the sector by 17% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$73.66 -
$81.56
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$73.17
Resistance Level
$76.16
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.00
Wall Street Target
$100.92
(+33.5%)
Revenue Growth (YoY)
5.9%
Earnings Growth (YoY)
-26.2%
Profit Margin
17.0%
Valuation Discount vs History
-7.4% cheaper
PE vs Historical
14.0 vs 17.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.4%
(market-implied from PE analysis)
1-Year Target
$70.01
(-7%)
2-Year Target
$64.83
(-14%)
3-Year Target
$60.03
(-21%)
3-Yr Target (if PE normalizes)
(PE: 14→18)
$75.44
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 8.0%)
$138.55
(+83%)
Base:
(SPY PE: 14.0, Growth: 8.0%)
$95.12
(+26%)
Bear:
(PE: 11.9, Growth: 8.0%)
$80.85
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 19.18 | Current EPS (TTM): $3.88
Bull Case
$113.88
(+51%)
Analyst growth 39.1%, PE expands to 21.1
Base Case
$103.53
(+37%)
Market implied 39.1%, PE stable at 19.2
Bear Case
$50.60
(-33%)
Severe decline -20.0%, PE contracts to 16.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.0 to 17.6
Stabilization Target:
$95.01
(+25.7%)
PE Expansion Potential:
+25.7%
Share & Embed Analysis
Last updated: October 03, 2026 10:47 AM ET
Data refreshes hourly during market hours. Next update: 11:47 AM
Data refreshes hourly during market hours. Next update: 11:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 69 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 64 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 58 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 38 SELL |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
